Cennet Biopharma Profile
Key Indicators
- Authorised Capital ₹ 3.65 Cr
as on 18-07-2024
- Paid Up Capital ₹ 2.25 Cr
as on 18-07-2024
- Company Age 7 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 17.97 Cr
as on 18-07-2024
- Revenue 52.02%
(FY 2023)
- Profit 114.18%
(FY 2023)
- Ebitda 734.01%
(FY 2023)
- Net Worth 42.53%
(FY 2023)
- Total Assets 11.86%
(FY 2023)
About Cennet Biopharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.65 Cr and a paid-up capital of Rs 2.25 Cr.
The company currently has active open charges totaling ₹17.97 Cr.
Vineet Gupta, Pradeep Goyal, Duraisamy Deepa, and One other member serve as directors at the Company.
- CIN/LLPIN
U24304DL2017PTC315853
- Company No.
315853
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Apr 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Cennet Biopharma Private Limited offer?
Cennet Biopharma Private Limited offers a wide range of products and services, including Pharma Ingredients & Raw Materials, Anti Inflammatory and Immunosuppressant API, Ayurvedic & Herbal Extracts, Plant Extracts.
Who are the key members and board of directors at Cennet Biopharma?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sachin Kumar  | Director | 01-Nov-2018 | Current |
| Vineet Gupta | Director | 10-Apr-2017 | Current |
| Pradeep Goyal | Director | 10-Apr-2017 | Current |
| Duraisamy Deepa | Director | 16-Aug-2021 | Current |
Financial Performance and Corporate Structure Insights of Cennet Biopharma.
Cennet Biopharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 52.02% increase. The company also saw a substantial improvement in profitability, with a 114.18% increase in profit. The company's net worth Soared by an impressive increase of 42.53%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cennet Biopharma?
In 2023, Cennet Biopharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Jai Shree Notebooks And Files Private LimitedActive 18 years 10 months
Vineet Gupta is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Indian Bank Creation Date: 10 Jan 2023 | ₹2.32 Cr | Open |
Others Creation Date: 09 Nov 2021 | ₹1.15 Cr | Open |
Indian Bank Creation Date: 26 Oct 2018 | ₹14.50 Cr | Open |
How Many Employees Work at Cennet Biopharma?
Cennet Biopharma has a workforce of 11 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cennet Biopharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cennet Biopharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
